曲妥珠单抗致重度血小板减少症一例及文献回顾

曾晓淇; 姜珊珊; 彭远洋; 刘民锋; 叶长生; 董建宇

doi:10.24920/003799

Your Location：

Home >

Browse articles >

曲妥珠单抗致重度血小板减少症一例及文献回顾

中国医学科学杂志（英文版） 2020年35卷第4期页码：377-382

Case Report | Updated：2024-04-10

- 曲妥珠单抗致重度血小板减少症一例及文献回顾
- Affiliations：
  
  1. 1Breast Center, Department of General Surgery, Nanfang Hospital,Southern Medical University, Guangzhou 510515, China
  2. 2Institute of Hematological Research, Shaanxi Provincial People’s Hospital, Xi’an 710000, China
- Author bio：
  
  * E-mail: djypumc@163.com; Tel: 86-20- 62787172.
- Funds：
  
  President Foundation of Nanfang Hospital, Southern Medical University;南方医科大学南方医院院长基金(2016L007)
- DOI：10.24920/003799
  中图分类号：
- 录用日期：2020-7-17，
  
  网络出版日期：2020-12-31，
  
  纸质出版日期：2020-12-31
- Accepted：
Scan QR Code
曾晓淇, 姜珊珊, 彭远洋, 等. 曲妥珠单抗致重度血小板减少症一例及文献回顾[J]. 中国医学科学杂志（英文版）, 2020,35(4):377-382.

Zeng Xiaoqi, Jiang Shanshan, Peng Yuanyang, et al. Trastuzumab-Induced Severe Thrombocytopenia:A Case Report and Literature Review[J]. Chinese medical sciences journal, 2020, 35(4): 377-382.
曾晓淇, 姜珊珊, 彭远洋, 等. 曲妥珠单抗致重度血小板减少症一例及文献回顾[J]. 中国医学科学杂志（英文版）, 2020,35(4):377-382. DOI： 10.24920/003799.

Zeng Xiaoqi, Jiang Shanshan, Peng Yuanyang, et al. Trastuzumab-Induced Severe Thrombocytopenia:A Case Report and Literature Review[J]. Chinese medical sciences journal, 2020, 35(4): 377-382. DOI： 10.24920/003799.

摘要

我们报告一例29岁浸润性导管癌pT2N0M0女性患者

ER和PR均弱阳性

Her-2（3+）

患者在我中心接受化疗和曲妥珠单抗治疗。于第二周期注射曲妥珠单抗6小时后出现异常子宫出血

血小板计数急剧降至3×10

临床确诊为曲妥珠单抗所致严重血小板减少症。给予输注血小板、糖皮质激素、缩宫素及升血小板药物治疗

11天后患者的血小板完全恢复正常。由于严重血小板减少症由曲妥珠单抗所致

患者终止并未再继续尝试曲妥珠单抗治疗。随着曲妥珠单抗在临床逐渐广泛应用

临床医生可能会越来越多地遇到由曲妥珠单抗引起的致命性严重血小板减少症。我们希望通过此病例报告和文献回顾

引起临床医生对此种情况的警惕和重视

助益提升治疗效果。

Abstract

We present a 29-year-old woman with pT2N0M0 breast cancer

histological diagnosis of invasive ductal carcinoma

ER and PR low positive

and HER-2 (3+). The patient developed trastuzumab-induced thrombocytopenia in 6 hours after an intravenous infusion of trastuzumab at the second cycle of trastuzumab treatment with the symptom of abnormal uterine bleeding. Laboratory exam revealed a sharp drop of platelet count down to 3×10

/L. With the treatment of single-donor platelet transfusions

glucocorticoids

oxytocin and thrombopoietic drugs

the platelet count recovered completely in 11 days. This case was confirmed to be severe thrombocytopenia induced by trastuzumab

and retreatment with trastuzumab was not attempted. With increasing clinical utilization of trastuzumab

clinicians are likely to encounter more life-threatening trastuzumab induced severe thrombocytopenia. By this case report and literature review

we hope to increase the awareness

attach the attentions to this condition

and help with the effective treatment.

关键词

Keywords

references

Bray F , Ferlay J , Soerjomataram I , et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries . CA Cancer J Clin 2018 ; 68 ( 6 ): 394 - 424 . doi: 10.3322/caac.21492. PubMed PMID: 30207593 10.3322/caac.21492. PubMed PMID: 30207593 . https://www.ncbi.nlm.nih.gov/pubmed/30207593 https://www.ncbi.nlm.nih.gov/pubmed/30207593

Feng RM , Zong YN , Cao SM , et al . Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond) 2019 ; 39 ( 1 ): 22 . doi: 10.1186/s40880-019-0368-6 10.1186/s40880-019-0368-6 .

Guo J , Li Q , Zhang P , et al . Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients . Chin J Cancer Res 2019 ; 31 ( 5 ): 759 - 70 . doi: 10.21147/j.issn.1000-9604.2019.05.06 10.21147/j.issn.1000-9604.2019.05.06 . DOI: 10.21147/j.issn.1000-9604.2019.05.06 http://doi.org/10.21147/j.issn.1000-9604.2019.05.06 https://www.ncbi.nlm.nih.gov/pubmed/31814680 https://www.ncbi.nlm.nih.gov/pubmed/31814680

Hudis CA . Trastuzumab: mechanism of action and use in clinical practice . N Engl J Med 2007 ; 357 ( 1 ): 39 - 51 . doi: 10.1056/NEJMra043186 10.1056/NEJMra043186 . https://www.ncbi.nlm.nih.gov/pubmed/17611206 https://www.ncbi.nlm.nih.gov/pubmed/17611206

Cameron D , Piccart-Gebhart MJ , Gelber RD , et al . 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial . The Lancet 2017 ; 389 ( 10075 ): 1195 - 205 . doi: 10.1016/s0140-6736(16)32616-2 10.1016/s0140-6736(16)32616-2 . DOI: 10.1016/S0140-6736(16)32616-2 http://doi.org/10.1016/S0140-6736(16)32616-2 https://linkinghub.elsevier.com/retrieve/pii/S0140673616326162 https://linkinghub.elsevier.com/retrieve/pii/S0140673616326162

Cathomas R , von Moos R . Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib . Ann Oncol 2009 ; 20 ( 9 ): 1606 - 7 . doi: 10.1093/annonc/mdp370 10.1093/annonc/mdp370 . DOI: 10.1093/annonc/mdp370 http://doi.org/10.1093/annonc/mdp370 https://www.ncbi.nlm.nih.gov/pubmed/19622591 https://www.ncbi.nlm.nih.gov/pubmed/19622591

Parikh O , Neave F , Palmieri C . Severe thrombocytopenia induced by a single infusion of trastuzumab . Clin Br Cancer 2008 ; 8 ( 3 ): 285 - 6 . doi: 10.3816/CBC.2008.n.034 10.3816/CBC.2008.n.034 .

Jara Sanchez C , Olier Garate C , Garcia-Donas Jimenez J , et al . Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease . Ann Oncol 2009 ; 20 ( 9 ): 1607 - 8 . doi: 10.1093/annonc/mdp374 10.1093/annonc/mdp374 . DOI: 10.1093/annonc/mdp374 http://doi.org/10.1093/annonc/mdp374 https://www.ncbi.nlm.nih.gov/pubmed/19633054 https://www.ncbi.nlm.nih.gov/pubmed/19633054

Drudi F , Gianni L , Fantini M , et al . Trastuzumab-related thrombocytopenia: always a self-limiting complication? Ann Oncol 2010 ; 21 ( 3 ): 668 - 9 . doi: 10.1093/annonc/mdp566 10.1093/annonc/mdp566 . DOI: 10.1093/annonc/mdp566 http://doi.org/10.1093/annonc/mdp566 https://www.ncbi.nlm.nih.gov/pubmed/20032121 https://www.ncbi.nlm.nih.gov/pubmed/20032121

Mantzourani M , Gogas H , Katsandris A , et al . Severe thrombocytopenia related to trastuzumab infusion . Med Sci Monit 2011 ; 17 ( 7 ):CS85-7. DOI: 10.12659/msm.881846 http://doi.org/10.12659/msm.881846 https://www.ncbi.nlm.nih.gov/pubmed/21709629 https://www.ncbi.nlm.nih.gov/pubmed/21709629

Pino MS , Angiolini C , Fioretto L . Severe thrombocytopenia after trastuzumab retreatment: a case report . BMC Res Notes 2013 ; 6 : 400 . doi: 10.1186/1756-0500-6-400 10.1186/1756-0500-6-400 . DOI: 10.1186/1756-0500-6-400 http://doi.org/10.1186/1756-0500-6-400 https://www.ncbi.nlm.nih.gov/pubmed/24093447 https://www.ncbi.nlm.nih.gov/pubmed/24093447

Zeng RC , Dai XX , Xie FY , et al . Severe thrombocytopenia induced by second exposure to trastuzumab can be alleviated by prolonging the interval between treatments . Clin Br Cancer 2014 ; 14 ( 2 ): e69 - 72 . doi: 10.1016/j.clbc.2013.11.004 10.1016/j.clbc.2013.11.004 .

Miarons M , Velasco M , Campins L , et al . Gradual thrombocytopenia induced by long-term trastuzumab exposure . J Clin Pharm Therapeut 2016 ; 41 ( 5 ): 563 - 5 . doi: 10.1111/jcpt.12416 10.1111/jcpt.12416 . DOI: 10.1111/jcpt.12416 http://doi.org/10.1111/jcpt.12416 http://doi.wiley.com/10.1111/jcpt.12416 http://doi.wiley.com/10.1111/jcpt.12416

Luo Q , Guo Z , Ye C . Thrombocytopenia induced by herceptin . Am Surg 2019 ; 85 ( 4 ): e222 - 4 . https://www.ncbi.nlm.nih.gov/pubmed/31043221 https://www.ncbi.nlm.nih.gov/pubmed/31043221

George JN , Raskob GE , Shah SR , et al . Drug-induced thrombocytopenia: a systematic review of published case reports . Ann Intern Med 1998 ; 129 ( 11 ): 886 - 90 . https://www.ncbi.nlm.nih.gov/pubmed/9867731 https://www.ncbi.nlm.nih.gov/pubmed/9867731

Aster RH , Bougie DW . Drug-induced immune thrombocytopenia . N Engl J Med 2007 ; 357 ( 6 ): 580 - 7 . doi: 10.1056/NEJMra066469 10.1056/NEJMra066469 . DOI: 10.1056/NEJMra066469 http://doi.org/10.1056/NEJMra066469 https://www.ncbi.nlm.nih.gov/pubmed/17687133 https://www.ncbi.nlm.nih.gov/pubmed/17687133

Aster RH , Curtis BR , McFarland JG , et al . Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management . J Thromb Haemost 2009 ; 7 ( 6 ): 911 - 8 . doi: 10.1111/j.1538-7836.2009.03360.x 10.1111/j.1538-7836.2009.03360.x . DOI: 10.1111/j.1538-7836.2009.03360.x http://doi.org/10.1111/j.1538-7836.2009.03360.x https://www.ncbi.nlm.nih.gov/pubmed/19344362 https://www.ncbi.nlm.nih.gov/pubmed/19344362

Neunert C , Terrell DR , Arnold DM , et al . American Society of Hematology 2019 guidelines for immune thrombocytopenia . Blood Adv 2019 ; 3 ( 23 ): 3829 - 66 . doi: 10.1182/bloodadvances.2019000966 10.1182/bloodadvances.2019000966 . DOI: 10.1182/bloodadvances.2019000966 http://doi.org/10.1182/bloodadvances.2019000966 https://www.ncbi.nlm.nih.gov/pubmed/31794604 https://www.ncbi.nlm.nih.gov/pubmed/31794604

Liu XG , Bai XC , Chen FP , et al . Chinese guidelines for treatment of adult primary immune thrombocytopenia . Int J Hematol 2018 ; 107 ( 6 ): 615 - 23 . doi: 10.1007/s12185-018-2445-z 10.1007/s12185-018-2445-z . DOI: 10.1007/s12185-018-2445-z http://doi.org/10.1007/s12185-018-2445-z https://www.ncbi.nlm.nih.gov/pubmed/29619624 https://www.ncbi.nlm.nih.gov/pubmed/29619624

浏览量

778

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

关联资源

UBE2C as an Immune-Related Biomarker for Breast Cancer: A Study Based on Multiple Databases